Invivyd, Inc. (IVVD)
- Previous Close
2.0700 - Open
2.0600 - Bid 2.1200 x 200
- Ask 2.1800 x 100
- Day's Range
2.0600 - 2.2300 - 52 Week Range
0.9800 - 5.1950 - Volume
323,790 - Avg. Volume
873,641 - Market Cap (intraday)
256.325M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.38
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
invivyd.comRecent News: IVVD
Performance Overview: IVVD
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVVD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVVD
Valuation Measures
Market Cap
256.33M
Enterprise Value
57.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.42%
Return on Equity (ttm)
-74.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-198.64M
Diluted EPS (ttm)
-1.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
200.64M
Total Debt/Equity (mrq)
1.22%
Levered Free Cash Flow (ttm)
-103.6M